CM
IONS icon

CM Management’s Ionis Pharmaceuticals IONS Stock Holding History

CM Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.12M Buy
+25,000
New +$1.42M 0.75% 49

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return

CM Management's IONS Position: Q3 2026 in Review

CM Management opened a new position in Ionis Pharmaceuticals (IONS) in Q3 2026: 25,000 shares worth $1.12M. The stake represents 0.75% of the portfolio and ranks #49 among its holdings.

351 funds tracked by Wall St. Rank hold IONS as of Q3 2026.

  • CM Management held 25,000 shares of Ionis Pharmaceuticals worth $1.12M as of Q3 2026.
  • Ionis Pharmaceuticals was a new CM Management position in Q3 2026.
  • Ionis Pharmaceuticals made up 0.75% of CM Management's portfolio in Q3 2026, its #49 holding.
  • 351 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2026.

Based on CM Management's 13F filing for Q3 2026, filed 12 Nov 2026.